Neuphoria Therapeutics (NEUP) Current Leases (2020 - 2025)
Neuphoria Therapeutics (NEUP) posted quarterly Current Leases of $85210.0 for Q3 2025, down 34.39% year-over-year from $129881.0 in Q3 2024, and down 26.74% quarter-over-quarter from $116314.0 in Q2 2025.
Neuphoria Therapeutics (NEUP) Current Leases (2020 - 2025) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Current Leases for 6 consecutive years, with $85210.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Current Leases fell 34.39% year-over-year to $85210.0; the TTM figure through Sep 2025 stood at $85210.0 (down 34.39% YoY), while the FY2025 annual figure was $116314.0, down 4.65% from the prior year.
- Current Leases slipped to $85210.0 in Q3 2025 per NEUP's latest filing, from $116314.0 in the prior quarter.
- Across five years, Current Leases topped out at $134157.5 in Q2 2021 and bottomed at $85210.0 in Q3 2025.
- Historically, Current Leases has averaged $117474.0 across 5 years, with a median of $118492.0 in 2024.
- Annual changes were most pronounced in 2021 — Current Leases tumbled 73.34% — and 2024, when it increased 6.22%.
- Neuphoria Therapeutics' Current Leases stood at $134157.5 in 2021, then decreased by 14.55% to $114631.6 in 2022, then increased by 0.19% to $114851.7 in 2023, then rose by 3.17% to $118492.0 in 2024, then fell by 28.09% to $85210.0 in 2025.
- Business Quant data shows NEUP's Current Leases at $85210.0 in Q3 2025, $116314.0 in Q2 2025, and $121738.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.54 Mn | 2.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 85,210.00 |
| Jun 30, 2025 | 116,314.00 |
| Mar 31, 2025 | 121,738.00 |
| Dec 31, 2024 | 118,492.00 |
| Sep 30, 2024 | 129,881.00 |
| Jun 30, 2024 | 121,990.00 |
| Jun 30, 2023 | 114,851.73 |
| Jun 30, 2022 | 114,631.58 |
| Jun 30, 2021 | 134,157.47 |
| Jun 30, 2020 | 503,173.62 |